Vinay Prasad: ‘If something is highly promising, is it unethical to test that?’ in Washington Post (2016)
The Oregonian (2017)
Portland Tribute (2016 & 2017)
Top 5 under 40. Sept 2017
A remedy for a sick industry. Peter Korn. Mar 3, 2016
Prasad takes do no harm oath to heart. Peter Korn Mar 3, 2016
On Ending Medical Reversal: When Evidence Says No, but Doctors Say Yes. In Propublica and the Atlantic Monthly. February 2017.
Book Reviews for Ending Medical Reversal (Hopkins Press, 2015)
Best Health Care Books of 2015. Dr. Kenny Lin. Dec 7, 2015
Ending Medical Reversal is Revolutionary. Dr. Kenny Lin. Nov 11, 2015
Preventing Flip-Flops in Clinical Practice: Q&A. MedPage Today. Nov 9, 2015
How Evidence Can Clean the House of Medicine. MedPage Today. Nov 9, 2015
Ending Medical Reversal Laments Flip Flopping. NY Times. Oct 30, 2015
A course in reversal. The Lancet. Mar 26, 2016
Cost to bring 1 cancer drug to market (JAMA Internal Medicine 2017)
What does it cost to bring a drug to market. NYTimes. Gina Kolata.
Cost to bring drug to market. Norman Swan.
Doctors Tweeting about Drugs While Being Paid By Maker (Lancet Oncology 2017)
FDA's breakneck pace increases uncertainty. HemOnc Today
Pharmaceutical advertisement for rare disease (JAMA 2017)
The Tricky Ethics of Big Pharma Soft-Selling on Soap Operas. WIRED magazine
Quoted regarding the fact 1/3 of FDA drugs later receive safety notifications
Quoted regarding the cost and efficacy of PCSK-9 drug Repatha
Cost of cancer drugs (Nature reviews 2017)
Will the cost of cancer drugs break the economy? Modern Healthcare
Financial Conflicts Among Doctors on Twitter (Coverage of our JAMA IM 2017 paper)
What your doctor isn't telling you on Twitter. Time Magazine.
OHSU study probes doctors' financial conflicts of interest on Twitter. Portland Business News.
Hidden Conflicts of Interest Found Throughout Medicine. MedPage Today
Quoted in Article about CAR-T cells
Patrick Soon Shiong's Moonshot has fallen short
Summary of multiple research papes
Dozens Of New Cancer Drugs Do Little To Improve Survival, Frustrating Patients. Liz Szabo. KHN. (2017)
Judging Cancer Drugs by Clinical Not Statistical Benefit (2016)
Judging Cancer Drugs. Medscape. Nov 4, 2016
Comments about FDA approval
Trump calls the FDA ‘slow and burdensome,’ but it’s faster than ever. Washington Post. 2017
FDA approval of $SRPT drug. Quartz. Nov 1, 2016
Future jobs of FDA’s haematology-oncology reviewers
When Drug Reviewers Leave The FDA, They Often Work For Pharma. Kaiser Health News. Sept 27. 2016.
Q&A: From FDA to Industry. The Scientist. Sept 27, 2016
The FDA's revolving door raises ethical questions. Modern Healthcare. Sept 27, 2016
FDA's Cancer-Drug Reviewers Often Join Industry Later: Study. Health Day. Sept 27. 2016
'Revolving Door' Between the FDA and Industry? Medscape. Sept 27, 2016
Is the FDA Too Cozy With Drug Companies? Time Magazine. Sept 28, 2016
STAT Recommends as a Must Follow Twitter Account (2016)
The rise of the unbranded pharmaceutical ad (CBS News)
Token Gesture when Disclosing Financial Conflict of Interest
Conflict of interest (JAMA Oncology 2016)
Screening for Lung Cancer (2016)
Family doctors don't always screen smokers for lung cancer. Fox News Health.
The FDA's Use of Untested Surrogate Endpoints (Mayo 2016)
Should Oncology Trials Rely Less on Overall Survival. Cancer Therapy Advisor
Study raises questions FDA standards on new cancer drugs. Milwaukee Journal Sentinel.
OHSU researcher: FDA's short-cut approval can lead to questionable cancer drugs. Portland Biz Journal.
We are spending 107 billion in cancer drugs, is it worth it? Washington Post
On Medical Errors Now the Third Leading Cause of Death (2016)
Superficial coverage of medical errors could leave erroneous impression with readers. Health news reviews May 2016.
Don't believe what you read. STAT. May 2016.
On Precision and Genomic Medicine (2016)
Genetics-based medicine a matter of debate Bend Bulletin. May 2016.
On Paradigm-HF and Milt Packer (2016)
Unbelievable Folly of Clinical Trials. Cardiobrief. March 2016
Cost of cancer drugs (2016)
This drug is defying a rare form of leukemia — and it keeps getting pricier. Carolyn Johnson. Washington Post. Mar 9, 2016
Cost of unused cancer drugs in the US. The Lancet. March 10, 2016
Characteristics and Conflicts of Public Speakers at ODAC (JAMA IM 2016)
Cancer drug testimonals tinged with financial interest. MJS. Feb 1, 2016
FDA should make it easier to hear patients voices. The Hill. Feb 25, 2016
Does Pharma Hijack Public Comment at FDA. Medscape. Feb 2016.
Criticism of PARADIGM HF & Entresso Ad
On NEJM's Notorious "Data Parasite" Editorial
NEJM Editor Backtracks on Data-Sharing 'Parasites' Editorial. Medscape Jan 26, 2016
New England Journal of Medicine increasingly targeted by critics. Boston Globe. Apr 5, 2016.
Why cancer screening has never been shown to “save lives” (BMJ 2016)
There is not enough proof screening works. Time Magazine. Jan 7, 2016
Cancer screening benefits are overstated, experts claim. The Guardian. Jan 6, 2016
It is Misleading to Say Cancer Screening Saves Lives. Newsweek. Jan 6, 2016
Application of Medicare’s New Technology Add-on Payment Program for Blinatumomab (JAMA Oncology 2015)
Medicare's NTAP for Blinatumomab Should Be Questioned. Medscape. December 30, 2015
With Hands Tied, CMS' NTAP for Blinatumomab Is Ridden With Controversy. AJMC. Jan 5, 2016
Characteristics of Exceptional or Super Responders to Cancer Drugs
Super-Responder Buzzkill: Some Likely Have Indolent Cancers. MedPage Today. Nov 19, 2015
Use of Superlatives in Cancer Research (JAMA Oncology 2015)
Cancer Reporting Needs Less Hype & More Hope. Real Clear Science. Jan 2016
'Miracle cures'? Nope, OHSU says, it's just art of the sale. Portland Tribune. Nov 12, 2015
If a new cancer drug is hailed as a breakthrough odds are its not. NPR Shorts. Oct 29, 2015
Glowing terms often used for new cancer drugs in health news. Reuters. Oct 29, 2015
‘Revolutionary.’ ‘Game changer.’ ‘Miracle.’ How much are we hyping unproven cancer drugs? Washington Post. Oct. 29, 2015
Miracle or hype? News reports often inflate cancer drugs' success. USA Today. Oct 29, 2015
What is the Most Hyped Drug in Cancer Care? Medscape. Oct. 29, 2015
Media Often Overplays Cancer Drug Research, Study Finds. US News and World Report. Oct 29, 2015
That breakthrough game-changing miracle cancer drug is likely nothing of the sort. Incidental Economist. Oct 29, 2015.
In Drug Ca News. Everything is Awesome! MedPage Today. Oct 29, 2015
OHSU: Some cancer drugs aren't the 'miracle' cures media makes them out to be. Portland Business Journal Oct 29, 2015
If A Cancer Drug Is Described As A Miracle, It Probably Isn't. Oregon Public Radio. Oct. 29, 2015.
Hard wired bias (Mayo Clinic Proceedings, 2015)
Top reads in slow medicine. MedPage Today. Nov 13, 2015
Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals (JAMA IM 2015)
Few cancer drugs demonstrate OS benefit at time of FDA approval. HemOnc Today. Dec 30, 2015
Slippery slope: A targeted therapy that misses its mark. MedPage Today. Dec 12, 2015
FDA repeatedly approved Affinitor without proof it extended life. MJS. Dec 12, 2015
Surrogates for Survival or Other Endpoints. JAMA Oncology. Nov 25, 2015.
Many cancer drugs may not help people live longer. NPR. Oct 23, 2015
Is 1 in 7 odds a breakthrough? Is it even promising? Health News Review.
Approved but not proven: What's up with FDA, cancer drugs? Medscape. Oct 22, 2015
Two-thirds of cancer drug approvals based on surrogate endpoints. APA. Oct 21, 2015
Early drug approvals can backfire. Boston Globe. Oct 20, 2015.
Study: Two-thirds of new cancer drugs don't extend life. Milwaukee Journal Sentinel. Oct 19, 2015
FDA Accelerated Cancer Drugs Don't Get Adequate Follow up. MedPage Today. Oct 19, 2015
Cost of cancer drugs
Why do Specialty Drugs cost so much, and what can we do about it? Rhode Island Public Radio. Oct 15, 2015
Quoted in article about the NIH SPRINT trial
Raised Hype about Lower Blood Pressure. Scientific America. Sept 21, 2015.
Panelist on the Diane Rehm's show regarding the controversy of treating DCIS
How Do We Treat Early Stage Breast Cancer? A New Study Revives The Debate. NPR. Aug 24, 2015
Strength of Association Between Surrogate Endpoints and Survival (JAMA IM, 2015)
Primary Care Physicians' Role in Counseling About Gun Safety (AAFP, 2015)
5 Years of Cancer Drug Approvals: Innovation, Efficacy, Cost (JAMA Onc, 2015)
Cancer Doctors Offer Way to Compare Medicines, Including by Cost. New York Times. June 22, 2015
Skyrocketing drug prices leave cures out of reach for some patients. USA Today. June 15, 2015
Study Finds Oncology Drug Pricing Models 'Not Rational' - The ASCO Post, Apr. 9th 2015
US Cancer Drug Prices 'not rational' - PMLive, Apr. 8th 2015
No Real Rationale for Rising Cancer Drug Prices, JAMA Researchers Conclude - FiercePharma, Apr. 7th 2015
Modern Drug Development: Which Patients Should Come First? (JAMA, 2014)
Targeting Drug Development - The Incidental Economist, Nov 25th 2014
Mortality and Treatment Patterns Among Patients Hospitalized With Acute Cardiovascular Conditions During Dates of National Cardiology Meetings (JAMA IM, 2014)
Some Heart Patients Do Better When the Cardiologist is Away - The LA Times, Dec 22nd 2014
Heart Care: Can Less Treatment Be Better? - USA Today, Dec 22nd 2014
The Withdrawal of Drugs for Commercial Reasons: The Case of Tositumomab, An Incomplete Story (JAMA IM 2014)
Bexxar for Lymphoma: Gone but Not Forgotten - Medscape, DATE
Comparative Effectiveness Questions in Oncology (NEJM, 2014)
Cancer Drug Trials That Should, But Won't, Be Done - Medscape, DATE
Cancer Drugs: Too Expensive to Compare? - Modern Healthcare, Apr 17th 2014
High costs of cancer drugs preclude study for cheaper alternatives - Oncology Practice, Apr 16th 2014
Evidence Based De-implementation (Implementation Science, 2014)
Time to Consign What Doesn't Work to the Trash Bin - Prevention Action, Apr 16th 2014 - Prevention Action, Apr 16th 2014
Media Coverage of Medical Journals: Does the Media Select the best stories? (PLOS, 2014)
US newspapers favor weaker studies, researchers say - British Medical Journal, Jan 24th 2014
Medical News: Evidence Not a Factor - Medpage Today, Jan 21st 2014
A Decade of Reversal: An Analysis of 146 Contradicted Practices (Mayo, 2013)
Medical Procedures may be Useless or Worse - The New York Times, July 26th 2013
Pressed To Demonstrate Utility, Digital Health Struggles -- Just Like Traditional Medicine - Forbes, Jan 7th 2014
Changes in Modern Medicine: What Can We Expect? - The Huffington Post, Jan 30th 2014
Studies often overturn accepted medical practice, analysis finds - British Medical Journal, July 26th 2013
Newly established medical practices often prove to be ineffective, study finds - The Minneapolis Post, July 31st 2013
More Medical Procedures that Don't Work - Men's Journal, Oct 2013
Reversal of established medical practice - Australian Broadcasting Company, July 29th 2013
The Inferior Vena Cava Filter (JAMA IM, 2013)
Filters often used to stop clots without evidence - Reuters, Mar 19th 2013
Vena Cava Filters: Little Evidence and Wide Variation in Use - Forbes, Mar 18th 2013
No Standard for Vena Cava Filter Use - Medpage Today, Mar 18th 2013
Chest Pain in the Emergency Room (Archives Internal Medicine, 2012)
Chest Pain in the Emergency Room - Heartwire, Date
The Diagnosis and Treatment of Pulmonary Embolism (Archives Internal Medicine, 2012)
Richard Lehman's Journal Review - British Medical Journal, July 9th 2012
Cardiovascular Primary Prevention (Archives Internal Medicine, 2012)
The Statis on Statins: Should Healthy Adults Over 50 Take Them? - Scientific American, May 21st 2012
Reversal of Contradicted Medical Practices (JAMA, 2012)
Bias and error are rampant in medical literature - KevinMD, Mar 18th 2012
The Frequency of Medical Reversal (Archives Internal Medicine, 2011)
So how often does medical consensus turn out to be wrong? - Retraction Watch, July 11th 2011
New Studies Often Reverse Existing Practices - Medpage Today, July 11th 2011
Health 'truths' overturned: New medical information might change some long-held beliefs (print only) - Consumer Reports on Health, 2011